Celgene Corporation
CELGENE CORP /DE/ (Form: 4, Received: 08/02/2013 17:47:40)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Alles Mark J
2. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [ CELG ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

7/31/2013
(Street)

SUMMIT, NJ 07901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/31/2013     M    558   A $54.85   5504   D    
Common Stock   7/31/2013     M    1393   A $58.04   6897   D    
Common Stock   7/31/2013     M    3657   A $58.53   10554   D    
Common Stock   7/31/2013     M    4875   A $73.55   15429   D    
Common Stock   7/31/2013     M    1219   A $49.61   16648   D    
Common Stock   7/31/2013     M    2392   A $62.42   19040   D    
Common Stock   7/31/2013     M    5000   A $71.82   24040   D    
Common Stock   7/31/2013     M    5000   A $57.80   29040   D    
Common Stock   7/31/2013     M    2500   A $50.36   31540   D    
Common Stock   7/31/2013     M    17787   A $38.47   49327   D    
Common Stock   7/31/2013     M    3438   A $39.01   52765   D    
Common Stock   7/31/2013     M    4583   A $46.02   57348   D    
Common Stock   7/31/2013     M    3437   A $54.55   60785   D    
Common Stock   7/31/2013     M    3438   A $56.99   64223   D    
Common Stock   7/31/2013     M    2577   A $61.48   66800   D    
Common Stock   7/31/2013     M    2577   A $52.34   69377   D    
Common Stock   7/31/2013     M    1718   A $57.88   71095   D    
Common Stock   7/31/2013     M    23333   A $59.50   94428   D    
Common Stock   7/31/2013     M    1718   A $51.53   96146   D    
Common Stock   7/31/2013     M    3125   A $73.92   99271   D    
Common Stock   7/31/2013     M    2081   A $72.93   101352   D    
Common Stock   7/31/2013     S    96406   D $147.01   (1) 4946   D    
Common Stock   8/2/2013     M    7500   A $70.63   12446   D    
Common Stock   8/2/2013     M    7500   A $62.35   19946   D    
Common Stock   8/2/2013     S    5000   D $146.467   14946   D    
Common Stock                  2614   I   401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $54.85   7/31/2013     M         558      (2) 1/9/2017   Common Stock   558   $0.00   (3) 0   D    
Stock Option (right to buy)   $58.04   7/31/2013     M         1393      (2) 4/10/2017   Common Stock   1393   $0.00   (3) 0   D    
Stock Option (right to buy)   $58.53   7/31/2013     M         3657      (2) 7/10/2017   Common Stock   3657   $0.00   (3) 0   D    
Stock Option (right to buy)   $73.55   7/31/2013     M         4875      (2) 10/9/2017   Common Stock   4875   $0.00   (3) 0   D    
Stock Option (right to buy)   $49.61   7/31/2013     M         1219      (2) 1/8/2018   Common Stock   1219   $0.00   (3) 0   D    
Stock Option (right to buy)   $62.42   7/31/2013     M         2392      (2) 4/8/2018   Common Stock   2392   $0.00   (3) 0   D    
Stock Option (right to buy)   $71.82   7/31/2013     M         5000      (2) 7/8/2018   Common Stock   5000   $0.00   (3) 0   D    
Stock Option (right to buy)   $57.80   7/31/2013     M         5000      (2) 10/14/2018   Common Stock   5000   $0.00   (3) 0   D    
Stock Option (right to buy)   $50.36   7/31/2013     M         2500      (2) 1/13/2019   Common Stock   2500   $0.00   (3) 0   D    
Stock Option (right to buy)   $38.47   7/31/2013     M         17787      (2) 4/1/2019   Common Stock   17787   $0.00   (3) 0   D    
Stock Option (right to buy)   $39.01   7/31/2013     M         3438      (2) 4/14/2019   Common Stock   3438   $0.00   (3) 0   D    
Stock Option (right to buy)   $46.02   7/31/2013     M         4583      (2) 7/14/2019   Common Stock   4583   $0.00   (3) 0   D    
Stock Option (right to buy)   $54.55   7/31/2013     M         3437      (2) 10/13/2019   Common Stock   3437   $0.00   (3) 1146   D    
Stock Option (right to buy)   $56.99   7/31/2013     M         3438      (2) 1/12/2020   Common Stock   3438   $0.00   (3) 0   D    
Stock Option (right to buy)   $61.48   7/31/2013     M         2577      (2) 4/13/2020   Common Stock   2577   $0.00   (3) 296   D    
Stock Option (right to buy)   $52.34   7/31/2013     M         2577      (2) 7/13/2020   Common Stock   2577   $0.00   (3) 860   D    
Stock Option (right to buy)   $57.88   7/31/2013     M         1718      (2) 10/12/2020   Common Stock   1718   $0.00   (3) 1720   D    
Stock Option (right to buy)   $59.50   7/31/2013     M         23333      (2) 12/27/2020   Common Stock   23333   $0.00   (3) 23334   D    
Stock Option (right to buy)   $51.53   7/31/2013     M         1718      (2) 1/31/2021   Common Stock   1718   $0.00   (3) 860   D    
Stock Option (right to buy)   $73.92   7/31/2013     M         3125      (2) 3/1/2022   Common Stock   3125   $0.00   (3) 7270   D    
Stock Option (right to buy)   $72.93   7/31/2013     M         2081      (2) 4/30/2022   Common Stock   2081   $0.00   (3) 6244   D    
Stock Option (right to buy)   $70.63   8/2/2013     M         7500      (2) 9/21/2017   Common Stock   7500   $0.00   (3) 0   D    
Stock Option (right to buy)   $62.35   8/2/2013     M         7500      (2) 11/23/2017   Common Stock   7500   $0.00   (3) 0   D    

Explanation of Responses:
( 1)  The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $146.78 to $147.23, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
( 2)  The option was fully exercisable.
( 3)  The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended).

Remarks:
Executive Vice President, Global Head Hematology and Oncology

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Alles Mark J
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901


See Remarks

Signatures
/s/Robert J Hugin______________________________ Robert J Hugin, Attorney-in-Fact 8/2/2013
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.